MET/EGFR Combo Beats Chemo in Resistant NSCLC Trial

A phase 3 randomized trial (NCT06110663) compared dalmelitinib plus aumolertinib against platinum-based chemotherapy in patients with EGFR-mutated, MET-amplified advanced NSCLC after progression on EGFR-TKIs. The trial reported median progression-free survival of 6.2 months with the combination versus 4.4 months with chemotherapy (HR 0.60), along with higher objective response rate (59.6% vs 38.6%) and longer duration of response (9.7 vs 4.4 months); overall survival data were immature, and grade 3 or higher adverse events occurred at similar rates (50.0% vs 51.0%) though toxicity profiles differed.

Most relevant for: Patients with EGFR-mutated, MET-amplified advanced NSCLC who have progressed on EGFR-TKI therapy.

Summary written by an AI model from the source text and dated by the source's publication date. Check the original before acting on it. How MedFollow selects and summarizes updates.

Informational only. Not medical advice. Not a substitute for clinical judgment. Always consult current guidelines and your own clinical judgment.